Analysts Offer Predictions for LRMR Q2 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Larimar Therapeutics in a report issued on Thursday, July 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.39) EPS and Q3 2027 earnings at ($0.36) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.22.

A number of other analysts have also recently weighed in on the company. Wedbush dropped their price target on Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Robert W. Baird reduced their price objective on Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. started coverage on Larimar Therapeutics in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $9.00 target price on the stock. Finally, Truist Financial raised shares of Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Larimar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.71.

Larimar Therapeutics Stock Up 1.6%

Shares of NASDAQ LRMR opened at $3.26 on Friday. The firm’s 50-day moving average price is $3.67 and its two-hundred day moving average price is $3.94. Larimar Therapeutics has a 52-week low of $2.71 and a 52-week high of $6.42. The stock has a market capitalization of $338.66 million, a P/E ratio of -1.58 and a beta of 0.84.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. grew its stake in shares of Larimar Therapeutics by 44.2% in the third quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company’s stock worth $98,861,000 after purchasing an additional 9,375,000 shares in the last quarter. Blue Owl Capital Holdings LP raised its stake in shares of Larimar Therapeutics by 16.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 6,823,690 shares of the company’s stock valued at $25,998,000 after purchasing an additional 970,650 shares in the last quarter. Millennium Management LLC lifted its holdings in Larimar Therapeutics by 7.2% in the fourth quarter. Millennium Management LLC now owns 5,206,364 shares of the company’s stock worth $19,836,000 after purchasing an additional 349,533 shares during the period. Opaleye Management Inc. grew its position in Larimar Therapeutics by 114.7% in the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company’s stock valued at $11,878,000 after buying an additional 2,195,923 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Larimar Therapeutics by 44.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,087,840 shares of the company’s stock valued at $9,974,000 after buying an additional 945,809 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.